Aptose Biosciences Inc. (APTO) Stock Price Down 0.5%
Aptose Biosciences Inc. (NASDAQ:APTO) shares traded down 0.5% on Wednesday . The stock traded as low as $2.04 and last traded at $2.11, with a volume of 58,960 shares traded. The stock had previously closed at $2.12.
Several research analysts have recently weighed in on the stock. Zacks Investment Research downgraded shares of Aptose Biosciences from a “hold” rating to a “sell” rating in a research report on Friday, August 12th. Royal Bank Of Canada reissued an “outperform” rating and issued a $23.00 target price on shares of Aptose Biosciences in a research report on Saturday, June 25th. Roth Capital raised shares of Aptose Biosciences from a “neutral” rating to a “buy” rating and lifted their target price for the stock from $4.00 to $8.00 in a research report on Monday, June 13th. Canaccord Genuity reissued a “buy” rating and issued a $7.00 target price on shares of Aptose Biosciences in a research report on Thursday, June 9th. Finally, Oppenheimer Holdings Inc. reissued a “buy” rating on shares of Aptose Biosciences in a research report on Thursday, June 9th. One equities research analyst has rated the stock with a sell rating and four have assigned a buy rating to the stock. Aptose Biosciences currently has a consensus rating of “Buy” and an average price target of $12.30.
The company has a 50 day moving average of $2.42 and a 200-day moving average of $2.60. The company’s market capitalization is $26.53 million.
Aptose Biosciences Inc (Aptose) is a clinical-stage biotechnology company. The Company is engaged in the development of anticancer drugs that target specific epigenetic processes and signal transduction abnormalities that underlie a particular life-threatening malignancy. Its product pipeline includes cancer drug candidates that exert activity as stand-alone agents and that enhance the activities of other anticancer agents without causing overlapping toxicities.
Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.